RxDoctor Payments DataLook up a doctor →

Michael Desvigne, MD

Plastic and Reconstructive Surgery · Glendale, AZNPI 1356336317

Payments from drug & device makers

$2,217,403in general payments, 2019–2025

Across 1,409 payments — averaging $1573.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Musculoskeletal Transplant Foundation Inc.$1.1M
  • KCI USA, Inc.$592K
  • Solventum Corporation$247K
  • Smith+Nephew$176K
  • Urgo Medical North America, LLC$55K
  • Aroa Biosurgery Incorporated$23K
  • plus $19K from 29 others
$35,120in research payments, 2019–2025

Across 1 payment — averaging $35,120 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Musculoskeletal Transplant Foundation Inc.$35K

What the payments were for

  • Consulting fees$1,247,41957%
  • Speaking & faculty fees$626,05928%
  • Travel & lodging$260,02212%
  • Food & beverage$52,4592%
  • Education$15,0731%
  • Entertainment$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,217,403 in reported general payments places this provider in the 95th percentile of 63 plastic and reconstructive surgery providers in Arizona.

See all plastic and reconstructive surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$22,995
Medicare patients
31
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.12$18,333
Cephalexin15$179
Ciprofloxacin Hcl30$125
Tramadol Hcl13$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$176,062$18,33312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 63 plastic and reconstructive surgery providers in Arizona.

Other plastic and reconstructive surgery in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →